B-type natriuretic peptide prevents postnatal closure of ductus arteriosus by both vasodilation and anti-remodeling in neonatal rats

doi:10.1042/CS20180201

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/32265

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32265

Title:	B-type natriuretic peptide prevents postnatal closure of ductus arteriosus by both vasodilation and anti-remodeling in neonatal rats
Authors:	Yeh, Jwu-Lai Wu, Jiunn-Ren Wu, Bin-Nan Yang, Sheau-Fang Dai, Zen-Kong Liou, Shu-Fen Hsu, Jong-Hau
Contributors:	Department of Pharmacology and Graduate Institute of Medicine, College of Medicine Department of Medical Research, Kaohsiung Medical University Hospital Kaohsiung Med Univ Hosp, Dept Med Res Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources Kaohsiung Med Univ Hosp, Dept Pediat Kaohsiung Med Univ, Coll Med, Fac Med, Dept Pediat I Shou Univ, E Da Hosp, Dept Pediat Kaohsiung Med Univ Hosp, Dept Pathol Chia Nan Univ Pharm & Sci, Dept Pharm
Keywords:	Smooth-Muscle-Cells Labedipinedilol-A Proliferation Hypertension Mechanisms Pathway Aldosterone Activation Migration Aorta
Date:	2018-09-28
Issue Date:	2019-11-15 15:47:23 (UTC+8)
Publisher:	PORTLAND PRESS LTD
Abstract:	The physiologic process of postnatal ductus arteriosus (DA) closure consists of vasoconstriction followed by vascular remodeling. We have recently reported that B-type natriuretic peptide (BNP), a potent vasodilator, also has anti-remodeling effects in pulmonary vasculature. However, its effects on DA have not been elucidated. We investigated whether BNP can prevent DA closure, and if so, the underlying mechanisms. Using in vivo studies, we examined effects of BNP (10 mg/kg, ip at birth) on DA closure in neonatal rats within 4 h after birth. We found that in control rats, the DA spontaneously closed at 4 h with a decreased DA diameter, enhanced intimal thickening, and luminal occlusion. BNP prevented DA closure at 4 h with a preserved DA diameter, attenuated intimal thickening, and preserved lumina! patency. Ex vivo, BNP attenuated oxygen-induced vasoconstriction of isolated DA rings of newborn rats. These vasodilating effects were blunted by Rp-8-Br-PET-cGMPS, a cGMP inhibitor. In vitro, BNP inhibited angiotensin II (Ang II)-induced proliferation and migration of DA smooth muscle cells (DASMCs). BNP inhibited Ang II-induced mitochondrial reactive oxygen species (ROS) production and calcium overload in DASMCs. Finally, BNP inhibited Ang II-induced ERK1/2 activation. These in vitro effects were antagonized by Rp-8-Br-PET-cGMPS. In conclusion, BNP prevents postnatal DA closure by both vasodilation and anti-remodeling through the cGMP pathway. The mechanisms underlying anti-remodeling effects include anti-poliferation and anti-migration, with attenuation of mitochondrial ROS production and intracellular calcium and ERK1/2 signaling. Therefore, the BNP/cGMP pathway can be a promising therapeutic target for clinical management of DA patency.
???metadata.dc.relation.uri???:	http://dx.doi.org/10.1042/CS20180201
Relation:	Plos One, v.132, n.18, pp.2045-2058
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1546	View/Open

Loading...